Clinical Trials Browser

Not yet recruiting × Lymphoma, B-Cell, Marginal Zone × obinutuzumab × Clear all

NCT06793189 2025-01-27

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Not yet recruiting

Lymphoma, B-Cell, Marginal Zone